Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SH-748 by Nanjing Sanhome Pharmaceutical for Marginal Zone B-cell Lymphoma: Likelihood of Approval
SH-748 is under clinical development by Nanjing Sanhome Pharmaceutical and currently in Phase I for Marginal Zone B-cell Lymphoma. According...